Vaccines - Eastern Africa | Statista Market Forecast

The Vaccines market in Eastern Africa is anticipated to achieve a revenue of US$694.00m in 2024.
Looking ahead, the market is expected to exhibit a compound annual growth rate (CAGR) of -11.44% from 2024 to 2029, leading to a market volume of US$378.00m by 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue, amounting to US$29.12bn in 2024.
Eastern Africa is experiencing a surge in demand for vaccines, driven by increasing awareness and government initiatives to improve healthcare access.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Vaccines against infectious diseases
Prophylactic and therapeutic vaccines
Flu vaccines
COVID-19 vaccines

Sera and gammaglobulins
Antivirals
Antibiotics

The Vaccines market in Eastern Africa has been experiencing significant growth in recent years.

Customer preferences: Customers in Eastern Africa are becoming increasingly aware of the importance of vaccination in preventing infectious diseases. This has led to a growing demand for vaccines in the region. Additionally, governments and international organizations have been investing heavily in vaccination campaigns to improve public health outcomes.

Trends in the market: One of the key trends in the Vaccines market in Eastern Africa is the increasing availability of vaccines. Pharmaceutical companies are expanding their operations in the region, and governments are working to improve vaccine distribution networks. This has made vaccines more accessible to people living in remote areas.Another trend in the market is the growing demand for new and innovative vaccines. As more people become vaccinated against common diseases, there is a need for vaccines that can prevent emerging infectious diseases. Pharmaceutical companies are investing in research and development to create new vaccines that can address these challenges.

Local special circumstances: One of the unique challenges facing the Vaccines market in Eastern Africa is the high prevalence of infectious diseases in the region. This has led to a greater emphasis on vaccination as a means of preventing the spread of disease. Additionally, the region has a large population of refugees and internally displaced persons, which has put a strain on healthcare resources.

Underlying macroeconomic factors: The Vaccines market in Eastern Africa is influenced by a number of macroeconomic factors. Economic growth in the region has led to an increase in healthcare spending, which has benefited the Vaccines market. Additionally, the region has a large and growing population, which has created a large market for vaccines. However, political instability and conflict in some parts of the region have created challenges for vaccine distribution and access.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.